Dr Lal PathLabs

January 30, 2021

National Stock Exchange of India
Limited Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex Bandra (E)
Mumbai – 400 051.

Bombay Stock Exchange Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Subject: Newspaper Publication(s)

Ref: Disclosure Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("Listing Regulations")

Dear Sir/Madam,

Pursuant to the Regulation 30 of SEBI Listing Regulations, please find attached copies of newspaper advertisement of Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2020, published in Financial Express and Jansatta on January 30, 2021.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary and Legal Head
Encl: As above

Dr Lal PathLabs
Financial Express
Date 30-01-2021
Page No - 3

Dr Lal PathLabs

Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388
Regd. Office: Block E, Sector-18, Rohini, New Delhi-110085
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram-122 001, Haryana
Phone: +91 124 3016500; **Fax:** +91 124 4234468; **Website:** www.lalpathlabs.com; **Email:** cs@lalpathlabs.com

Extract of Consolidated Unaudited Financial Results for the quarter & nine months ended 31 December, 2020

(Rs. in million except as stated)

S. No.	Particulars	3 months ended 31 December, 2020	Nine months ended 31 December, 2020	Corresponding 3 months ended 31 December, 2019
		(Unaudited)	(Unaudited)	(Unaudited)
1	Total Income from Operations	4,659	11,881	3,417
2	Net Profit for the period before Tax and Exceptional items#	1,289	2,836	734
3	Net Profit for the period before Tax and after Exceptional items#	1,289	2,836	734
4	Net Profit for the period after Tax and after Exceptional items#	959	2,114	549
5	Total Comprehensive Income for the period after tax#	959	2,114	550
6	Paid up Equity Share Capital (face value of Rs. 10/- per share)	833	833	833
7	Earnings Per Share (of Rs. 10/- each) (not annualised)			
	(a) Basic (In Rs.)	11.44	25.23	6.56
	(b) Diluted (In Rs.)	11.41	25.16	6.55

Before non-controlling Interest

Notes:

i. Key numbers of the Standalone Results are as under:

(Rs. in million except as stated)

S. No.	Particulars	3 months ended 31 December, 2020	Nine months ended 31 December, 2020	Corresponding 3 months ended 31 December, 2019
		(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from Operations	4,417	11,246	3,237
2.	Profit for the period before Tax	1,241	2,694	686
3.	Profit for the period after Tax	927	2,014	511
4.	Total comprehensive income	927	2,015	511

ii. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 29 January, 2021.

iii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', prescribed under Section 133 of the Companies Act, 2013.

iv. The above is an extract of the detailed format of Quarterly and nine months financial results as per Ind AS filed with the Stock Exchange under Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015. The full Financial Results of the Quarter and nine months ended is available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and the Company's website (www.lalpathlabs.com).

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited

Place: Gurugram
Date: 29 January, 2021

(Hony) Brig. Dr. Arvind Lal
Executive Chairman

Dr. lal pathlabs

Jansatta

Date. 30.1.2021

Page. No. 10

Dr Lal PathLabs

Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388
Regd. Office: Block E, Sector-18, Rohini, New Delhi-110085
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram-122 001, Haryana
Phone: +91 124 3016500; **Fax:** +91 124 4234468; **Website:** www.lalpathlabs.com; **Email:** cs@lalpathlabs.com

Extract of Consolidated Unaudited Financial Results for the quarter & nine months ended 31 December, 2020

(Rs. in million except as stated)

S. No.	Particulars	3 months ended 31 December, 2020	Nine months ended 31 December, 2020	Corresponding 3 months ended 31 December, 2019
		(Unaudited)	(Unaudited)	(Unaudited)
1	Total Income from Operations	4,659	11,881	3,417
2	Net Profit for the period before Tax and Exceptional items#	1,289	2,836	734
3	Net Profit for the period before Tax and after Exceptional items#	1,289	2,836	734
4	Net Profit for the period after Tax and after Exceptional items#	959	2,114	549
5	Total Comprehensive Income for the period after tax#	959	2,114	550
6	Paid up Equity Share Capital (face value of Rs. 10/- per share)	833	833	833
7	Earnings Per Share (of Rs. 10/- each) (not annualised)			
	(a) Basic (In Rs.)	11.44	25.23	6.56
	(b) Diluted (In Rs.)	11.41	25.16	6.55

Before non-controlling Interest

Notes:

i. Key numbers of the Standalone Results are as under:

(Rs. in million except as stated)

S. No.	Particulars	3 months ended 31 December, 2020	Nine months ended 31 December, 2020	Corresponding 3 months ended 31 December, 2019
		(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from Operations	4,417	11,246	3,237
2.	Profit for the period before Tax	1,241	2,694	686
3.	Profit for the period after Tax	927	2,014	511
4.	Total comprehensive income	927	2,015	511

ii. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 29 January, 2021.

iii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', prescribed under Section 133 of the Companies Act, 2013.

iv. The above is an extract of the detailed format of Quarterly and nine months financial results as per Ind AS filed with the Stock Exchange under Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015. The full Financial Results of the Quarter and nine months ended is available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and the Company's website (www.lalpathlabs.com).

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited

Place: Gurugram
Date: 29 January, 2021

(Hony) Brig. Dr. Arvind Lal
Executive Chairman